The level of VEGF was decreased in chronic ischemic kidney disease, resulting in kidney function deterioration and microvascular rarefaction.140 However, VEGF is also a key anti-tumor drug target and the restoration of VEGF might pose a risk.141 Therefore, other mechanisms regulating vascular rarefaction need to be discovered. Here, VEGFA is linked to neoplasm.